21.72
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Precedente Chiudi:
$20.95
Aprire:
$21
Volume 24 ore:
1.62M
Relative Volume:
0.79
Capitalizzazione di mercato:
$2.18B
Reddito:
$352.57M
Utile/perdita netta:
$-143.01M
Rapporto P/E:
-12.00
EPS:
-1.81
Flusso di cassa netto:
$-153.40M
1 W Prestazione:
+4.67%
1M Prestazione:
+29.59%
6M Prestazione:
-16.40%
1 anno Prestazione:
-32.48%
Beam Therapeutics Inc Stock (BEAM) Company Profile
Nome
Beam Therapeutics Inc
Settore
Industria
Telefono
857-327-8775
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Confronta BEAM con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BEAM
Beam Therapeutics Inc
|
21.72 | 2.11B | 352.57M | -143.01M | -153.40M | -1.81 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-28 | Aggiornamento | BofA Securities | Neutral → Buy |
2025-03-10 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
2025-01-29 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
2024-11-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
2024-07-23 | Iniziato | H.C. Wainwright | Buy |
2024-01-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
2023-12-08 | Downgrade | Jefferies | Buy → Hold |
2023-10-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2023-10-20 | Downgrade | Leerink Partners | Outperform → Market Perform |
2023-03-21 | Iniziato | Bernstein | Mkt Perform |
2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
2022-12-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2022-12-13 | Iniziato | Citigroup | Buy |
2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
2022-04-28 | Iniziato | Credit Suisse | Neutral |
2022-01-05 | Iniziato | Guggenheim | Buy |
2021-10-19 | Iniziato | SVB Leerink | Outperform |
2021-09-24 | Ripresa | Stifel | Buy |
2021-09-10 | Iniziato | BofA Securities | Buy |
2021-05-11 | Iniziato | Redburn | Buy |
2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
2021-02-16 | Iniziato | Wells Fargo | Overweight |
2021-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
2021-01-06 | Iniziato | Stifel | Hold |
2020-08-05 | Iniziato | William Blair | Outperform |
2020-03-02 | Iniziato | Barclays | Overweight |
2020-03-02 | Iniziato | JP Morgan | Overweight |
2020-03-02 | Iniziato | Jefferies | Buy |
2020-03-02 | Iniziato | Wedbush | Outperform |
Mostra tutto
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
Will Beam Therapeutics Inc. stock benefit from interest rate changesFree Market Dynamics Reports - jammulinksnews.com
What makes Beam Therapeutics Inc. stock attractive to long term investorsSuperior stock selection - jammulinksnews.com
What institutions are buying Beam Therapeutics Inc. stock nowOutperformance with explosive growth - jammulinksnews.com
What analysts say about Beam Therapeutics Inc. stockFree Popular Stock Recommendations - PrintWeekIndia
Trading (BEAM) With Integrated Risk Controls - news.stocktradersdaily.com
Can Beam Therapeutics Inc. stock recover from recent declineFree Smart Trading Workshop - jammulinksnews.com
Beam Therapeutics Inc. Stock Analysis and ForecastFree Stock Movement Tracking - Autocar Professional
What drives Beam Therapeutics Inc. stock priceDynamic investment opportunities - jammulinksnews.com
Is Beam Therapeutics Inc. a good long term investmentRobust financial gains - jammulinksnews.com
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company - MSN
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
(BEAM) Trading Report - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - MSN
H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT - MSN
Cathie Wood’s ARK ETF bolsters Beam stock, sheds Roblox - Investing.com
Beam Therapeutics: A Base Editing Breakthrough With Catalysts to Ignite Value - AInvest
Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease Trial - MSN
Beam Therapeutics Acquires Early-Stage Life Sciences Firm - The Globe and Mail
H.C. Wainwright reiterates Buy rating on Beam Therapeutics stock at $80 target - Investing.com
Beam Therapeutics: A Contrarian Opportunity in Gene Editing Amid Russell Reconstitution - AInvest
Top 10 CRISPR Stocks to Buy Now - Insider Monkey
Beam Therapeutics Inc.(NasdaqGS: BEAM) dropped from Russell 3000 Value Index - MarketScreener
3 Promising Genomics Stocks to Keep an Eye On in 2025 - The Globe and Mail
Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):